A Life-changing Way to Treat COPD/ Emphysema
FDA approved in 2018, with over 20,000 patients treated globally, the Zephyr Valve is proven to help improve your patient’s lung function, exercise capacity and quality of life—without surgery and many of its associated risks.20
If you treat patients with severe COPD and emphysema, we’re here to help. Request a call to speak to a Zephyr Valve representative in your area.
GOLD 2020: Level A Evidence rating affirms that endobronchial valves, like the Zephyr Valve, are a viable, minimally invasive treatment option for severe emphysema, a form of COPD.
Who Qualifies for the Zephyr Valve?
Patients who meet the following criteria should be evaluated for treatment with endobronchial valves:1-5
- Breathless despite optimal medical management (mMRC≥2)
- A confirmed diagnosis of COPD
- Non-smoking or willing to quit smoking
- Have an FEV1 ≤50% predicted
For more detailed information on clinical data and patient selection criteria please download our free resources.
How It Works
The Zephyr Lung Valve is a new category of treatment for COPD and emphysema. Despite taking the best available medications, many patients with emphysema are still short of breath. This is caused by hyperinflation of the lungs and depression of the diaphragm.
The Zephyr Valves reduce lung hyperinflation by allowing trapped air to escape and preventing new air from entering that diseased lobe. The remaining lobes are then able to expand more fully and work more efficiently, reducing pressure on the diaphragm and improving overall lung function.
If you’d like to learn more about how the Zephyr Endobronchial Valve
treatment can help your patients, our dedicated specialists are here to help.
Helping Patients Combat Breathlessness
As symptoms of COPD become more severe, medications and oxygen therapy are often not enough. Lung volume reduction surgery is a big decision that comes with many associated risks. Zephyr Valves provide a minimally invasive alternative that can improve lung function and quality of life without the need for lung volume reduction surgery or lung transplantation.1
If you’re ready to start the referral process, we’re happy to help.
The Zephyr Endobronchial Valve
Shows Clinically Significant Benefits
- 4 randomized clinical trials published using preselection tools to qualify appropriate patients1-5
- Published in the New England Journal of Medicine, The Lancet, and The American Journal of Respiratory and Critical Care Medicine1-5
- Statistically significant and clinically meaningful improvements compared to standard of care in multiple trials1-4
- GOLD 2020: Level A Evidence rating
- Treatment success seen in a broad range of primary and secondary endpoints1-5
|RCT||Design||Sample size & follow-up period||Procedural Success (TLVR%)||Difference Zephyr Valve vs. Control Groups (ITT)|
MCID = 10%-15%
MCID = 26 m
MCID = -4 pts
Heterogeneous & Homogeneous
*Data on file at PMX (not in publication)
**Completed cases, all other values listed are ITT population
T Difference between valve and control groups
If you have a patient with COPD that you would like to have
evaluated for treatment with the Zephyr Valve, please connect with us.
Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.
See What Zephyr Valve Patients are Saying
20,000 People Have Been Treated with the Zephyr Valve
My pulmonologist, Dr. Teresa Heatly, first mentioned the Zephyr Valves to me because she thought I might be a candidate. I really trust her, and I was definitely interested in anything that might help.”
“ It’s been four months and I am shocked at how good I am breathing. I can have a long phone conversation, walk outside to get the mail, change the bedsheets, and do it all without oxygen.”
The procedure went well and frankly was much easier than the huge surgery I had been preparing for before the valves were an option.”
Still have questions? We’re here to help.